At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 18 enrolled

Drug / intervention

imatinib mesylatedrug

Likely dose

Imatinib mesylate 400 mg orally twice daily for 10–14 daysAI-extracted

Key inclusion· 6

✓Age ≥18 years
✓Suspected or confirmed DFSP diagnosis; if suspected, must be confirmed by pathology before treatment starts
✓Medically able to undergo surgical resection and resection is recommended for clinical management
✓At least one site of measurable (macroscopic) disease

Key exclusion· 8

✕Planned radiation therapy to the DFSP site prior to resection
✕Grade III/IV cardiac problems (e.g., congestive heart failure, MI within 6 months)
✕Pregnancy or breast-feeding
✕Severe and/or uncontrolled medical disease (uncontrolled diabetes, chronic renal disease, active infection) that may worsen with imatinib

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00243191

NCT00243191Phase 2Completed

Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans

Sarcoma Alliance for Research through Collaboration·interventional·Posted Oct 21, 2005·Updated Mar 29, 2012

In Brief

A Phase 2 clinical trial evaluating imatinib mesylate for Dermatofibrosarcoma Protuberans. Completed, enrolled 18 participants across 4 sites.

The purpose of this study is to examine the effect of imatinib on dermatofibrosarcoma protuberan tumors.

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

CountriesUnited States

Collaborators--

Phase 2CompletedFinished

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

First PostedOct 2005

Enrollment StartMay 2006

Primary CompletionSep 2009

TodayJul 2026

First PostedOct 21, 2005

Enrollment StartMay 1, 2006

Primary CompletionSep 1, 2009

TodayJul 2, 2026

Enrollment to primary: 3.3 yearsPosted 20.7 years ago

imatinib mesylatedrug

400 mg orally twice a day for 10 - 14 days